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The Sick Adipocyte Theory:  
The Forces of Clustering at Glance 
Valmore Bermúdez et al.* 
Endocrine and Metabolic Diseases Research Center, The University of Zulia, Maracaibo,  
Venezuela 
1. Introduction 
The concept and repercussions of Obesity have evolved alongside Humankind. First seen as 
an advantageous trait in the beginning of time, it´s now a double edged sword definition 
that shows how slowly genometabolic traits are acquired and how quickly can 
environmental factors turn it around.  Being obese is not only a matter of Body Mass Index 
(BMI) and adiposity, its influence stretches out to include  type 2 Diabetes Mellitus (T2DM), 
Psychological disorders like depression, anxiety disorders, and other eating disorders, 
Osteoarticular problems, Metabolic Syndrome, Cardiovascular Diseases (CVD) like 
hypertension, stroke, and myocardial infarction, Neurological disorders, Cancer, and even 
Immunity-related issues, such as low grade inflammation (Must, 1999; Oster, 2000; 
Thompson, 2001; Marchesini, 2003; Adami, 2003; Niskanen, 2004;  Panagiotakos, 2005).  
Obesity has been rising slowly yet steadily ever since the Industrial revolution and its pace 
has increased since the dawn of the 20th Century. Even though nutritional disorders have 
plagued Man, it was common to see that undernutrition and malnourishment were the 
higher numbers around the globe. Yet, the tables were turned when Gardner & Halweil 
published in 2000 that the number of excess-weight patients surpassed the number of the 
underweight population, welcoming Humanity to the supersized phase of the land of milk 
and honey (O´Dea, 1992). In 2006, the World Health Organization reported that by 2005 1.6 
billion above 15 years of age would be overweight and at least 400 million would be obese, 
while it is predicted to reach 2.3 billion of overweight and over 700 million of obese adults 
by the year 2015 (World Health Organization [WHO], 2006). The figures published by Kelly 
et al, 2008 darken the scope, predicting that by 2030 1.12 billion individuals will be obese 
and 2.16 million will be overweight. 
There are many factors that have influenced the increasing prevalence of obesity worldwide, 
and have influenced the scientific community to coin the term obesogenic environment 
(Egger & Swinbum, 1997) as the external factors that act as “second hit” triggers in the 
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multifactorial theory of obesity (see Figure 1). Many factors have been nominated and 
proven key to the etiology of obesity, such as dietary energy intake, physical activity, 
intrauterine environment (fetal programming), and other comorbidities like alcohol intake, 
physical disabilities, endocrine disorders, drug treatments, among others (Pi-Sunyer, 2002; 
Caballero, 2007). Physical activity has become fundamental in the intervention strategies for 
primary (Pate et al., 1995) and secondary prevention (Thompson, 2003) in obese patients, 
since it has been portrayed as a major independent risk factor for coronary artery disease 
(Fletcher et al., 1992). It can be defined as any voluntary skeletal muscle movement that 
consumes energy, usually measured by at least 30 minutes of physical activity that 
consumes at least 4 METs (i.e. brisk walk) (Dunn et al., 1998). On the contrary, physical 
inactivity (sedentarism) is the lack of these ~ 30 minutes of energy consumption a day 
(Dunn et al., 1998), resulting in positive energy balance. 
 
 
Fig. 1. The Two Hit proposal of obesity. A subject who is genetically-prone to obesity – 
either due to a monogenic syndrome, associated polymorphisms or imprinting (as seen in 
utero) have the first hit intrinsically. If he is subject to an obesogenic environment and 
subsequently develops an obesogenic behaviour (second hit), the end result will be 
progressive weight gain till obesity values are achieved. The obesogenic factors include high 
fat/carbohydrate diet, low physical activity, alcohol and smoking habits. 
One of the interesting aspects about the term “physical activity” is that it´s used as an 
interchangeable term between “cardiorespiratory fitness”, but they aren´t defined equally 
nor do they have the same impact on the patients. Physical activity relates to energy 
expenditure while cardiorespiratory fitness relates to oxygen supplition by the heart. 
However, both terms can relate to the same definition but they don´t explain the same 
aspects. In a meta-analysis by Williams, 2001 concludes that these terms should be treated as 
different and independent risk factors, findings that are similar to those reported by Hein et 
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al., 1992 concerning 4,999 men who were followed for 17 years in the Copenhagen Male 
Study, using physical fitness and leisure time physical activity as risk factors for ischemic 
heart disease (IHD). This team reported that being very fit offers no protection to IHD when 
sedentary, and being unfit and sedentary offers higher risk for this disease. Other studies 
have examined the relationship between fitness and sedentarism [Fletcher et al., 1996; 
Rosengren et al., 1997; Pollock et al., 2000; Blair et al., 2001)  demonstrating without a doubt 
that sedentarism has been underestimated for a long time (Saltin, 1992).  
2. Set 
A sedentary patient is a real conundrum, and each one is unique especially if 
overweight/obese. Adiposity varies in degree and distribution, being classified according to 
anatomical location as subcutaneous and visceral adipocytes, each with a different metabolic 
profiling. 
2.1 Adipocytes  
Classically, white adipose tissue – adipocytes are recognized as the lipid-storing 
professional cells, and we remark professional because other types of cells can accumulate 
lipids yet it is not their main objective, as can be seen with myocytes, β-cells and neurons. 
The key feature of the mature adipocyte is that it can store fat without compromising its 
integrity or anatomy. The ontogeny of the adipocytes is still poorly understood, yet the 
process is being researched relentlessly (Gregoire et al., 1998; Darlington et al., 1998; 
Godínez-Gutiérrez et al., 2002)].  Mesenchymal stem cells differentiate into adipoblasts, 
which subsequently express early transcription markers and enter the preadipocyte I phase; 
the markers for the preadipocytes are α2Col6, Lipoprotein lipase, IGF-1 and Krox20. Once 
the cell´s fate has been decided, mitosis and clonal expansion begins entering the pre-
adipocyte II phase, characterized by active C/EBPβ/γ, SREBP-1, PPARγ2 and KLF5. Maturity 
of the cell cannot begin until it leaves the cell cycle and starts differentiation in coordination 
with upregulation of late markers which induce cell arrest and begin lipid accumulation: 
C/EBPα, GLUT4, Perilipin, TNF-α, TGF-β, lipogenic and lipolytic enzymes. The mature 
adipocyte develops when the markers include the expression and adipocyte-related 
hormones, cytokines and enzymes related lipid storage and release towards blood 
circulation. Perhaps the most interesting aspect of adipocyte differentiation is how 
preadipocytes are driven towards adipocyte profile (Fu et al., 2004; Simons et al., 2005; Sethi 
et al., 2007), which is all a gameplay of members of the Peroxisome-Proliferator-Activated-
Receptors and the CCAAT-enhancer-binding protein (C/EBP) families. The first step is the 
short-term expression of C/EBPβ and C/EBPγ2, followed closely by C/EBPα which 
activates PPARγ2, responsible for the adipogenesis genetic program. The sterol-response-
element-binding-protein-1c (SREBP1c) activates the lipogenic program through PPARγ, 
finalizing the accomplishment of the differentiated phenotype; see Figure 2. 
The mature adipocyte (Gregoire, 2001; Kershaw et al., 2004; Halberg et al., 2008) is a very 
specialized cell which is the center of energy storage and provision mechanisms, which is 
under a very tight central and peripheral control. Besides the basic anatomical role, the 
adipocytes are also endocrine cells which secrete several factors including leptin, adipsin, 
angiotensinogen, adiponectin, TNF-α, acylation stimulation protein, SPARC (secreted 
protein acidic and rich in cysteine), and PGAR/FIAF (PPARγ, Angiopoietin related/fasting-
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induced adipose tissue). This adipocyte secretome incorporates adipose tissue to 
immunologic processes with low grade inflammation phenomena and autoimmunity-
related diseases, and angiogenesis due to synthesis of angiogenic factors, various effects 
from macrophagic-related substances, extracellular matrix deposition and metalloproteinase 
remodeling (Frünbeck et al., 2001; Kershaw, et al., 2004). Given these features is not unusual 
to find that adipose tissue is part of several axes  such as the adipo-insular axis (Kieffer et al., 
2000; Vickers et al., 2001) [36-37], the adipocyte-vessels-brain axis (Elmquist et al., 2004; 
Guzik et al., 2007; Mietus-Snyder et al., 2008), and the adipocyte-myocyte axis (Sell et al., 
2006; Taube et al., 2009).  
 
 
Fig. 2. Adipogenesis. The mature adipocyte goes through several stages of maturation until 
the professional lipid-storing profile is achieved. The interplay between CCAAT-enhancer 
binding protein (C/EBP) isoforms with Peroxisome-Proliferator-Activated Receptor-γ 
(PPARγ) ensures the progression towards final differentiation once the preadipocyte II has 
left the cell cycle. As long as Cyclin D1 is active, progression to a G0 phase will be difficult – 
almost impossible – since this factor inhibits the differentiation transcription factors. 
Thiazolinilediones (TZD) are known agonists of the PPARγ enhancing the adipogenic 
program. 
2.2 Myocytes 
Sarcomeres are the functional elements of muscles cells. The contractile unit is composed of 
myosin fibers and actin, whose interaction allows the shortening of itself, displaying as a 
contracted myocyte. There are several classifications for muscle cells (Scott et al., 2001), yet 
the biochemical differentiation is discussed here. Muscle fibers are classified (Pette & Staron, 
1997; Bassel-Budy & Olson, 2006) in Type I, Type IIa, Type IId/x, and Type IIb, having 
www.intechopen.com
 
The Sick Adipocyte Theory: The Forces of Clustering at Glance 
 
7 
particular metabolic properties, a) fast-twitch glycolytic fibers (types IIx and IIb), b) fast-
twitch oxidative fibers (type IIa), and c) the slow-twitch oxidative fibers (type I). 
Dynamically, muscle fibers are classified as slow-twitch and fast-twitch motor units, and the 
fast fibers are subdivided in fast-twitch fatigue-resistant, fast-twitch fatigue-intermediate, 
and fast-twitch fatigable. Humans have a mixture of these muscle fibers and the number 
changes as the weight/metabolic profile is modified throughout life. Obese subjects are 
known to have few type I fibers and more type IIb fibers compared to lean subjects (Hickey 
et al., 1995). Tanner et al., 2001 reported that obese African-American women had low levels 
of type I fibers, and lower levels compared to obese Caucasian women, which reflects that 
fiber content also varies according to ethnicity. 
Skeletal muscle is more than just the motor unit which gives us the possibility of movement, 
it´s also the most important tissue for glucose disposal, making it an essential part in energy 
metabolism (DeFronzo et al., 1985) and the primary target for insulin-resistance related 
disturbances (Lillioja et al., 1987). The disposal of glucose into skeletal muscle is fiber-
specific, being greater in type I fibers compared with type IIa and IIb (Song et al., 1999) [50]. 
Type I/slow twitch oxidative myocytes are more efficient in regards of insulin binding, 
enhanced insulin receptor and post-receptor cascade activities, and higher GLUT4 
translocation, compared to Type II/fast-twitch glycolytic myocytes; this suggests that 
insulin´s actions are more oxidative than glycolytic. Type II muscle fibers are insulin resistant 
(Henriksen et al., 1990; Henriksen & Holloszy, 1991) giving a partial explanation to the 
insulin resistance observed in obesity, which is also associated with abnormal lipid 
partitioning and intramuscular lipid accumulation.  
2.3 The sick and the dying 
In obesity, myocytes are sick while adipocytes die slowly due to asphyxiation. The 
interaction of both is what makes the adipocyte-myocyte axis so important in obesity and 
related diseases including Type 2 Diabetes; see Figure 3. 
Plasticity – the ability to non-reversibly adapt to external load/pressure – can be seen in 
adipocytes, expressed as hypertrophy and hyperplasia (Arner et al., 2010). In overfed states, 
adipose tissue´s capacity to store excessive energy safely reaches its limit, causing a “spill-
over” effect all over the body. This nutritional overload mechanism and subsequent damage 
can be seen in models for catch-up growth (Dulloo et al., 2009; Summematter et al., 2009), 
where refeeding states are associated with hyperinsulinemia, lipogenesis, plasma membrane 
switching from polyunsaturated fatty acids to saturated fatty acids, increased triglyceride 
production, ending in adipocyte hypertrophy and glucose intolerance. How plasticity can be 
associated to insulin-resistance is a very complex scenario. Genetic background – thriftiness – 
is a strong influential factor (Lindsay et al., 2001; Kadowaki et al., 2003; Prentice et al., 2005). 
Thrifty related genes and metabolic profiles ensure that all excess energy ingested will be 
“efficiently” stored, reminiscing those famine/feast days of the hunter-gatherers or the 
postnatal days of intrauterine-growth-restricted newborns. Thrifty traits have many targets 
(Prentice et al., 2005), yet 2 are essential: metabolic thrift, which is focused on mitochondrial 
electronic transport, protein turnover, fuel channeling, and substrate cycling, and 
adipogenic thrift, which relates to proneness of fat gain.  
The physiological adaptation to overnutrition is not without intricacy, since 2 theories have 
been proposed. The adipokine dysregulation conveys the fact that overfed states triggers 
changes in the quantum and quality of the substances expressed in the adipocyte, for 
example, adiponectin secretion is lowered in obesity (Arita et al., 1999; Weyer et al., 2001), 
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while resistin´s is enhanced (Steppan et al., 2002; Vendrell et al., 2004). The second theory is 
based on ectopic fat accumulation of lipids in myocytes, hepatocytes and β-cells, where 
intramyocellular lipids correlates to insulin resistance (Virkamäki et al., 2001; Moro et al., 
2008).  
The continued stimulus and lipid accumulation makes the adipocyte (140 – 180 µm in 
diameter [Brook et al., 1972]) hypertrophy but the size of the cell is limited by the oxygen 
supply. Hypoxia (Hosogai et al., 2007) and increase synthesis of secretory proteins 
(Marciniak & Ron, 2006) are the main cause for adipocyte´s endoplasmic reticulum (ER) 
stress via the unfolded protein response (UPR) pathway. The latter proposal is quite simple 
to grasp since never-ending signals for secretion goes awry when the unfolded protein in 
the ER lumen surpasses the folded proteins quota due to a) lack of necessary components 
for the synthetized molecule, b) frequency of the secretion signal, and 3) shortage of 
chaperone proteins due to “sequestration” within the abnormal proteins accumulated 
within the lumen. This traffic alteration has been linked to several diseases including Type 2 
diabetes (Scheuner & Kaufman, 2008), Tumor hypoxia and prognosis (Koumenis & Wouters, 
2006), Alzheimer´s (Kudo et al., 2006) and Parkinson´s Disease (Ryu et al., 2002).  
In 2004, Trayhurn & Woods suggested for the first time that it was hypoxia the culprit for 
low-chronic inflammation of obesity, conveying that as the adipose tissue advances and the 
outer sectors become hypoxic, inflammatory cytokines and acute phase proteins are locally 
secreted to enhance angiogenesis and stop the vicious cycle. Hypoxia in adipose tissue is 
due to hypoperfusion, especially after the 100 µm diameter phase of the hypertrophic 
adipocyte, suggesting that achieving 180 µm is a hypoxic state (Ye et al., 2007). In adipose 
tissue, low oxygen levels can alter gene expression, being related to decreased adiponectin 
mRNA, which is controlled by C/EBP and is inhibited by UPR-induced CHOP (C/EBP 
homologous protein) (Hosogai et al., 2007). It also can modify adipocyte secretome (Wang et 
al., 2007), resulting in enhanced expression of Hypoxia Induced Factor-1α (inducing GLUT1 
mRNA), IL-6, leptin, Plasminogen activator inhibitor 1 (PAI-1), and Vascular Endothelial 
growth factor (VEGF), while haptoglobin and adiponectin are markedly decreased. Taking 
this one step further, hypoxia inhibit insulin post-receptor cascade though HIF-1α and HIF-
2, which is thought to be crucial for the insulin resistance state observed in obese patients 
(Regazzetti et al., 2009); this is mediated by lowered autophosphorylation of the insulin 
receptor by means yet to be understood, but apparently it involves the mTOR (mammalian 
target of rapamycin) (Dann et al., 2007), S6K pathway (Um et al., 2006) and subsequent 
activation of NF-κB (Michiels et al., 2002). Almost 6 years later, hypoxia is now known to be 
a glucose metabolism modulator, which at first can induce glucose uptake – via GLUT1 
synthesis and export – but can later decreased due to IRS-1 and insulin receptor 
phosphorylation, while at the same time, it can induce free fatty acid (FFA) release, leading 
to adipocyte dysfunction and worsening of peripheral insulin resistance (Yin et al., 2009; 
Copps et al., 2009). 
To finally dissect adipocyte´s cyanotic life, macrophages enter the picture. Adipose tissue is 
not a homogenous organ, in fact is very heterogeneous and is populated with adipocytes, 
fibroblasts, vascular endothelia and immunologic cells. One of these, are the macrophages, 
who contribute significantly to the inflammatory array of signals being sent from the 
adipocyte (Weisberg et al., 2003). Insulin resistance depends of the abdominal adipose tissue 
distribution and plasticity, rather than pre-adipocyte and small adipose cells (Hauner, 2010). 
Adipose tissue macrophages are responsible perpetuating pre-adipocyte state and 
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differentiation signal (Lacasa et al., 2007), by secreting TNF-α and IL-1, known suppressors 
of the adipogenic program via NF-κB which quashes PPARγ dependent genes. 
Macrophage´s secretome include VEGF, TNF-a, IL-1b, IL-6, reactive oxygen species (ROS), 
and prostaglandins. Monocyte recruitment towards the adipose tissue is regulated by many 
molecules, but C-C motif chemokine ligand 2 (CCL2) and its receptor (CCR2) are perhaps 
the most important ones (Bruun et al., 2005), so importantly that blocking macrophage 
infiltration surrounding dead/dying adipocytes is a proper therapeutic goal (Bruun et al., 
2005).  
 
 
Fig. 3. The Sick and the Dying. This diagram depicts the effects of elevated free fatty acids 
(FFA) and hyperglycemia on adipocytes and myocytes, as it is observed in obese patients. 
Once the injury is fixed and has reach a point of no return, both cells begin plasticity to cope 
with the hostile environment. The sick myocyte loses sarcomeres at the expense of 
intramyocellular lipid droplets, which are source of acyl~CoAs, diacylglycerol (DAG) and 
ceramides, who in turn focus on serine/threonine phosphorylation of Insulin receptor and 
IRS-1, blunting the insulin pathways – becoming insulin resistant- Meanwhile, the growing 
adipocyte becomes hypoxic, releasing several cytokines who in turn affect myocyte´s 
already weaken metabolism, perpetuating the metabolic disturbance. As the adipocytes die 
in the sidelines of the adipose tissue, macrophages are recruited, worsening the 
inflammatory microenvironment.  
The progressive growth and demise of adipocytes have collateral damage – a very sick 
insulin resistant skeletal myocyte. The sick myocyte not only has impaired insulin signaling, 
but also decreased expression of myogenin (muscle-specific transcription factor involved in 
myogenesis), IL-6, IL-8 and MCP-1 (monocyte chemotactic protein), with higher ceramides 
levels and lower mitochondrial capacity (Sell et al., 2008). How the muscle becomes insulin 
resistant is (still) a matter of debate, even though several mechanisms have been proposed. 
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Sir Phillip Randle (1963) was the first one to formulate a theory trying to explain how fuel 
substrates changed in muscle and how this would explain skeletal muscle insulin resistance 
(Randle et al., 1963). The Randle´s Hypothesis (glucose-fatty acid cycle) proposes that FFA 
compete with glucose as fuel substrate for mitochondrial oxidation, increasing β-oxidation 
within the myocyte. The consumption of FFA would in turn inhibit pyruvate 
dehydrogenase and phosphofructokinase, acting as barriers in the glycolytic pathway and 
reduced glucose uptake and oxidation. Over 30 years later, Shulman, 2000 singlehandedly 
dethroned Randle´s hypothesis, by stating that low FFA intramyocellular metabolism or 
enhanced lipid uptake leads to cytosolic accumulation of metabolites such as diacylglycerol, 
ceramides and acyl~CoA, which in turn activate serine/threonine kinase (PKC) cascade that 
end with the phosphorylation and inhibition of Insulin Receptor and IRS-1, blunting insulin 
post-receptor pathways, decreasing PI3-k activation and glucose uptake via GLUT4.  
Beyond the glucose utilization bluntering, others morphological changes occur within the 
sick myocyte. Skeletal muscle also shows plasticity traits, anatomical and functional. It can 
use glucose or lipids for fuel production; however, in obesity lipid oxidation is decreased 
due to diminished enzyme capacity and reduced carnitine-palmitoyl transferase 1 (CPT1) 
activity (Kelley et al., 1999). Triglyceride (TAG) accretion in muscle can be attributed to 2 
causes: reduced fatty acid oxidation (Kim et al., 2000) or enhance TAG synthesis (Hulver et 
al., 2003). Intramyocellular lipids (IMCL) are a far better predictor of muscular insulin 
resistance than BMI or waist-hip ratio (Pan et al., 1997), and it inversely correlates to visceral 
visfatin levels (Varma et al., 2007). IMCL turnover determines the amount of accumulation 
inside the myocyte, which modulates the level of lipid metabolites that can alter the PI3K 
pathways, via activation of PKC isotypes. Breakdown of the IMCL results in acyl~CoAs 
which can be readily oxidized in mitochondria (Guo, 2007), but it has been reported that 
obese mitochondria are slow oxidizers (mitochondrial dysfunction [Rabøl et al., 2010; Pagel-
Langenickel et al., 2010]) and are positioned in different parts of the cytosol, slowing 
oxidation and increasing the cytosolic lipid droplet, making this lipid handling alteration a 
metabolic risk for insulin resistance (Koonen et al., 2010). There is a paradox in this whole 
IMCL issue: highly trained athletes use IMCL as a source for energy during exercise (Klein 
et al., 1994), so it makes for quite a riddle. Since from a sports point of view IMCL is 
advantageous, then the harm is not whether the IMCL are formed or not, it´s the availability 
of toxic lipid intermediates. 
Now, how does a dying adipocyte, full of TAG and choking on ER stress, can make the 
susceptible myocyte sick? Since adipose tissue is considered an endocrine organ, then cross-
talks with other organs is plausible. The first evidence of this dialogue was published by 
Dietze et al., 2002 using skeletal myocytes cultured in the same medium as adipocytes. They 
reported a profound disturbance in insulin signaling, characterized by nulled insulin-
stimulated phosphorylation of IRS-1, reduced Akt activation, inducing an insulin resistant 
state. Several of the adipokines have been implicated in the process, including TNF-α 
(Hotamisligil, 1999), resistin (de Luis et al., 2009), IL-6 (Rotter et al., 2003), leptin 
(Shimomura et al., 1999), adiponectin (Yamauchi et al., 2001), MCP-1 (Sartipy et al., 2003) 
and RBP-4 (Graham et al., 2006), among others. One important feature between adipose-
induced muscle insulin resistance is the role of the macrophages, which are slowly 
becoming pivotal for (adipose) and skeletal muscle insulin resistance. Macrophages cultured 
with palmitate serum medium secrete major proinflammatory cytokines that lower insulin 
action (Samokhvalov et al., 2009) via JNK mediated decreased phosphorylated Akt (Varma 
et al., 2009). SIRT1, a member of the Sirtuin family of NAD-dependent deacetylases, is able 
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to blunt macrophages capacity for inducing insulin resistance in Zucker fatty rats, shedding 
light to the complex axis (Yoshizaki et al., 2010). All in all, adipokine mediators are able to 
induce reversible (regeneration of myotubes and IL-6 secretion) and irreversible (IL-8 and 
MCP-1 secretion and myogenin expression) changes in the muscle proteome promoting 
insulin resistance in the myocyte (Sell et al., 2008; Kewalrami et al., 2010).  
3. Go 
3.1 Glycemic control 
Physical activity and diet are the primary tools to intervene and modify lifestyle in the obese 
patient, yet it’s not exclusive, since these strategies can also be applied to type 2 diabetics, 
hypertensive patients, and other insulin-disturbances related diseases. Physical activity can 
be defined as any daily activity undertaken for at least 30 minutes a day that ends in caloric 
consumption, and it´s deficiency is considered an individual risk factor for cardiovascular 
disease (Carnethon, 2009). It has been proposed the basic etiology of complex diseases is 
associated with disturbances of oxygen metabolism (Koch & Britton, 2008), making 
cardiorespiratory fitness a fine predictor for health risk (Lee et al., 2005), metabolic 
syndrome  (LaMonte et al., 2005) and type 2 diabetes (Sawada et al., 2010). Regular exercise 
improves glycemic control, weight reduction and manages metabolic risks associated with 
adiposity. The molecular basics for this improvement have been extensively reviewed 
somewhere else (Hayashi et al., 1997; Hamilton et al.; 2000, Rose et al., 2005) and are shown 
in Figure 4. The mechanisms that are at play to ensure glucose uptake and consumption 
seem redundant since it centers on the translocation of GLUT4 towards the membrane, 
enhanced by AMPK, Ca++/Calmodulin dependent protein kinase , and Nitric Oxide, and act 
as insulin mediators during and after exercise mediating increases glucose and fatty acid 
oxidation (Turcotte & Fisher, 2008). The main destination of glucose uptake is to replenish 
the glycogen stores in the skeletal muscle, and it does not depend on insulin signaling, since 
there is no increase IRS-1, IRS-2 or PI3K activation.  
Focusing on the muscle fibers, constant exercise is known to induce a switch of muscle fibers 
towards the type I ones. Fiber shifts are thought to be the end result of fast myosin chain 
induction, with concomitant reduction of slow type I myosine. This muscle functional 
plasticity can be induced by any type of exercise, endurance, sprint or heavy resistance 
(Andersen et al., 1994; Fitts, 2003). The basic changes of fibers is characterized by reduction 
of type IIb percentage with slow increase of type IIa and type I, turning muscle metabolism 
into an oxidant kind over time, and become resistant to fatigue since the myocyte recovers 
from “metabolic stunnedness” and efficiently synthetizes ATP during and after exercise. 
The mechanisms underlying these adaptations are still poorly understood, but it is possible 
that AMPK and calcineurin activate parallel pathways that control myocyte adaptation 
(Röckl et al., 2007).  
AMP-activated protein kinase (AMPK) is a pivotal regulator of intracellular energy during 
stressful states like starvation, hypoxia, exercise, among others, and it is central in the 
hormonal control of metabolic processes that consume or produce ATP (Lim et al., 2010). 
AMPK is active when AMP/ATP ratio rises, inhibiting ATP consuming pathways and 
enhancing ATP producing processes like glucose and FFA oxidation. During exercise, 
AMPK is activated and immediately phosphorylates and inhibits acetyl~CoA carboxylase 
(ACC), the key enzyme that synthetizes malonyl~CoA – negative allosteric modulator of 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
12
CPT1. Once CPT1 is released from control, β-oxidation continues full force (Musi et al., 
2001). AMPK also modulates glycogen synthesis by increasing glucose availability inside the 
cell via phosphorylation and inhibition of Akt-Substrate 160 (AS160), main break for 
translocation of GLUT4 vesicles, and, regulates IMCL breakdown via phosphorylation of 
Hormone sensitive lipase (Jørgensen et al., 2006). And on a final note, AMPK can modulate 
the expression of GLUT4 by regulating GLUT4 enhancer factor (GEF) and myocyte enhancer 
factor 2 (MEF2) (Holmes et al., 2005) guaranteeing an appropriate glucose-uptake 
phenotype. Calcineurin – cyclosporine-sensitive, calcium-regulated serine/threonine 
phosphatase – is an enzyme that controls the signaling pathway for myogenic processes by 
modulation of the MyoD and MEF2 transcription factors (Chin et al., 1998), considered 
fundamental for fiber remodeling (Schiaffino et al., 2002; Bassel-Duny et al., 2003) with 
PPARδ as downstream effector (Wang et al., 2004).  
 
 
Fig. 4. Molecular basics of exercise. Once the AMP/ATP rises continuously according to 
muscle workout, AMPK kinase (AMPKK) is activated, alongside Ca++/calmodulin 
dependent Kinase (CaMK), both known to phosphorylate the a-subunit of AMPK, activating 
it.  AMPK then inhibits by phosphorylation Acetyl~CoA Carboxilase, enzyme known to 
synthetize malonyl~CoA, main negative modulator of carnitine-palmitoyl transferase 1 
(CPT1); blocking malonyl~CoA synthesis, β-oxidation is enhanced, using free fatty acids 
(FFA) from circulation and from lipid storage inside the myocyte. Secondly, AMPK activates 
PPARγ coactivator 1α (PGC-1α) which co-induces the PPARγ adipogenic program. Next, 
AMPK phosphorylates and activates endothelial Nitric Oxide Synthetase, which generates 
nitric oxide which serves as a vasodilator (increasing and maintaining blood flow) and is 
also an enhancer of GLUT4 translocation. Finally, AMPK phosphorylates Akt Substrate 160 
(AS160), who is blocking Rab-GTPase molecule from initiating the movements of the GLUT4 
vesicles towards the membrane. Once AS160 is “neutralized”, GLUT4 are exported to the 
plasma membrane, increasing glucose uptake. 
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Insulin sensitivity restoration is a bit more complicated.  Muscle straightening activity has 
been known to enhance sensitivity among adults, serving as proper program to reduce 
insulin resistance (Cheng et al., 2007). Glucose uptake and IMCL turnover have been 
implicated, yet there is paradox lingering around, endurance athletes have higher 
intramuscular lipids but are highly insulin sensitive (Goodpaster et al., 2001; Meex et al., 
2010). Now, this beneficial effect can be obtained whether acutely – daily muscle contraction 
inducer energy flux – and by chronic modifications – mitochondrial oxidative capacity and 
induced GLUT4 expression (Thyfault, 2008; Jiang et al., 2010).  
3.2 Thriftiness 
As we have formerly mentioned, exercise is associated with modification of gene 
expression, specially affecting genes that control energy deposit and consumption, even in 
high training statuses. The Thrifty genotype theory published in 1962 (Neel, 1962) proposed 
that genes that favored energy saving during feast/famine cycles in the Late Paleolithic Era 
were incorporated into the human genome, because they were advantageous during famine 
phases. Exercise can modify gene expression according to the type of activity exerted, for 
example, aerobic exercise (endurance) is not associated with increased phosphorylated 
p70S6K, but high resistance work-out is indeed related (Sherwood et al., 1999). Wendorf & 
Goldfine, 1991 proposed that during those hunter-gatherers years a selective insulin 
resistance in muscle had to be imposed, to avoid hypoglycemia during fasting and allow 
energy storage during feeding, traits that would turn disastrous in a sedentary individual, 
such as the obese patient.  Evidence of this theory can be seen in different racial groups all 
around the world. The Arizona Pima Indians have the highest prevalence of diabetes in the 
world with increased sedentarism, compared to the Mexican Pimas (Valencia et al., 1999) 
and the scenario is similar with the Pacific Islanders in Asia (Zimmet et al., 1990). Needless 
to say, physical inactivity is then associated with insulin resistance and the genetic 
implications of exercise and its mediators are an important aspect of the whole concept, and 
in desperate need of continuous investigation (Abate et al., 2003; Chakravarthy et al., 2004). 
3.3 Inflammation 
Other metabolic changes are observed during physical training in obese patients, such as 
anti-inflammatory effects. In previous sections, the low-grade inflammation 
characteristically seen in obesity was discussed.  Pedersen et al., 2007 reported that since the 
muscle was able to release cytokines under exercise conditions, these signaling molecules 
should be named myokines and the para/endocrine effects should be separated from their 
usual physiological profile.  
Interleukin-6 is perhaps the most important of these myokines, yet the muscle is known to 
secrete IL-8, IL-15, IL-10 and IL-1ra, and very intense exercise can induce TNF−α secretion 
(see Table 1) (Petersen et al., 2005; Marini et al., 2010). The IL-6 expression and release patter 
is astounding, with a 100-fold level in response to exercise. The dilemma lies in this: how 
does a known insulin resistance-mediating molecule can exert protective effects? The 
answer lies in the true inflammatory levels and profiles. It has been suggested that IL-6 
plays a villain role in the metabolic syndrome, alongside TNF-α. Nevertheless, Kubaszek et 
al., 2003 reported that the risk genotypes for metabolic disturbances (including obesity and 
type 2 diabetes) are characterized by increased transcription of TNF-α with decreased 
expression of IL-6. Now, the reader needs to me reminded that TNF-α triggers the release of 
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IL-6, not the other way around, so it´s logical to conclude that adipocyte derived TNF-α 
induces local expression of IL-6 in the adipose tissue (Pedersen et al., 2007), which correlates 
with the fact that IL-6 is not overtly elevated in diabetic patients and is not highly expressed 
in lean patients with insulin resistance (Carey et al., 2004). The insulin-sensitizing effects of 
IL-6 are still controversial, yet it has been reported that the myokine enhances glucose 
uptake and glycogen synthesis in the myocyte, via activation of AMPK while reducing TNF-
α levels (Pedersen et al., 2007). 
 
Myokine Locus Effect 
IL-6 7p21 
Anti-inflammatory when secreted before TNF-α (Carey et al., 
2004; Pedersen et al., 2007). 
IL-8 
4q12-
q13 
Angiogenesis and neutrophil chemoatraction thru the CXCR2 
(Freydelund et al., 2007). 
IL-15 4q31 
Reduction of body fat, especially visceral body fat (Carbó et al., 
2001; Acharyya et al., 2004) 
IL-10 
1q31-
q32 
Downregulation of Proinflammatory cytokines and chemokines 
(de Vries, 1995; Acharyya et al., 2004) 
IL-1ra 2q14.2 
Restriction and modulation of the inflammatory response during 
exercise (Ostrowski et al., 1999; Opal et al., 2000; Suzuki et al., 
2000) 
Table 1. Myokines and their effects concerning Obesity and Metabolic Syndrome. 
Parallel to IL-6 effects, IL-15 has progressively risen as a major modulator of fat metabolism 
and muscle accretion in skeletal muscle over the past 15 years, which have been discussed 
elsewhere (Carbó et al., 2000;  Quinn et al., 2008; Argilés et al., 2009), yet the following 
aspects need to be discussed. IL-15 is a cytokine which is related to NK cell maturation, 
which actions are not reserved for the immunology universe. This protein is synthetized 
also by placenta, muscle and other tissues, supporting the idea of non-immune functions in 
such organs. Muscle hypertrophy at the expense of myotube accretion by inhibition of 
protein degradation is observed in animal models (Quinn et al., 2002), and this has been 
proposed as a therapeutic option for wasting syndromes such as cancer (Carbó et al., 2000) . 
This effect is probably due to induction of PPAR-δ which mediates protein synthesis in such 
cells. As for adipose tissue, the cytokine has been related to reduce lipid accumulation in 
pre-adipocytes enhancing their differentiation, and inducing adiponectin secretion in 
matured adipocytes (Quinn et al., 2005). These findings were further confirmed, when it was 
proven that IL-15 effect also reached brown adipose tissue, with an acute induction of 
thermogenesis via upregulation of Uncoupling Proteins 1 and 3, PPAR-δ and –α and a final 
association with reduction of white adipose tissue mass (Almendro et al., 2008). The 
evidence pointed to a more multifaceted muscle-adipose axis with IL-15 as remote 
modulator (Quinn et al., 2009) when secreted from skeletal muscle, inducing GLUT4, 
enhancing glucose utilization, reducing adipose deposition and adipocyte size. Further 
studies have linked polymorphisms of IL-15 and metabolic syndrome propensity, including 
the following protein SNPs: rs1589241, rs1057972 (Pistilli et al., 2008), with a unique relation 
to metabolically obese normal weight patients (Di Renzo et al., 2006).  
On a final note, a new twist in the metainflamamtion phenomena (Hotamisligil, 2006) observed 
in obesity has been described. The innate receptors members of the Pattern Recognition 
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Receptor Family, the NLRPs, are part of an ancestral detection system which recognizes 
danger associated molecules, resulting in the recruitment of Caspase-1 and the activation of 
IL-1β and IL-18, known proinflammatory cytokines (Lamkanfi & Dixit, 2009). Receptor 
NLRP3 has been associated to lipotoxicity sensing by recognizing ceramides production in 
macrophages and adipocytes, contributing to obesity-related inflammation by synthesis of 
IL-1β and blunted insulin signaling in liver and adipose tissue (Vandanmagsar et al., 2011). 
Moreover, IL-1β has been proven to regulate adipogenesis towards a more insulin resistance 
phenotype (Stienstra et al., 2010), which renders fundamental in a proinflamatory and toxic 
environment which is seen around the hypoxic and pre-adipocyte rich areas of adipose 
tissue.  
4. Conclusions 
Obesity is a multifactorial disease, characterized by adiposity-related consequences and 
disease, such as type 2 diabetes, cardiovascular disease, obstructive sleeping apnea, 
osteoarthritis, and cancer. Understanding the molecular dialogue between the 2 principally 
affected cells – adipocyte and skeletal myocyte – serves as the underlying scientific platform 
to understand why physical activity is beneficial and mandatory in these patients. The very 
notion that glucose uptake is enhanced in skeletal muscle during and after exercise provides 
a great glycemic control strategy, lowering the effects of excessive glucose in circulating 
plasma, like glycosylated hemoglobin levels (Andrade-Rodríguez et al., 2007; Sigal et al., 
2007), increases plasma glutamine and arginine levels for the production of NO and 
glutathione not only improving vasodilation properties but also increasing antioxidant 
defenses (Krause & de Bittencourt,, 2008), and myocyte-derived IL-6 enhances glucose 
induced insulin secretion (Newsholme et al., 2010). 
The application of a proper exercise program in obese patients, along with diet and lifestyle 
modification, ensures that the obese myocyte will get in shape, with a dynamic IMCL 
turnover, improved glucose and fat oxidation, genetic modulation of fiber remodeling, 
ending in progressive and sustained metabolic control. The dying myocytes will stop being 
so stressed with external stimuli and over-availability of substrates, decreasing in size and in 
oxygen requirements, modulating macrophage recruitment and inflammatory signals 
derived from them. The application of therapeutic drugs to improve the effects of exercise 
and act synergistically has been reported.  
Thiazolidinediones (TZD) are a group of drugs that activate PPARγ, modulating all the 
downstream genes regulated by the transcription factor, including acyl~CoA synthetase, 
phosphoenolpyruvate carboxykinase and lipoprotein lipase, inducing FFA capture and 
storage in de novo adipocytes, lowering FFA levels in plasma at the cost of fast 
redistribution (“Lipid-steal” phenomenon) (Bermúdez et al., 2010). In insulin resistant 
models, TZD correct impaired myocyte insulin action (Zierath et al., 1998), normalize 
muscular insulin sensitivity and GLUT4 synthesis in conjunction with exercise (Hayener et 
al., 2000), lower waist-hip ratio due to a selective increase in lower body fat (Shadid et al., 
2003), improve exercise capacity in type 2 diabetic patients (Regensteiner et al., 2005), and 
increase adiponectin levels (Yang et al., 2002) just as exercise does (Kriketos et al., 2004; 
Højbjerre et al., 2007); which is why the combination of a TZD and exercise are self-
complementary in the treatment of insulin resistance (Lessard et al., 2007).  The world-
famous biguanide, Metformin, is the other pharmacological candidate to enhance exercise 
effects on the insulin resistance milieu. Exercise has been known to improve metformin 
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effects (Tang et al., 2001), acting as co-adjuvants in the reduction of the incident of diabetes 
(Doggrell, 2002), increasing vascular function and lowering Ischemia Coronary Artery 
Disease patients (Jadhay et al., 2006), and finally, both can reduce the expression of the fat 
transporter FAT/CD36, blunting the progression of ceramides-mediated insulin resistance 
in myocyte (Smith et al., 2007). The insulin sensitizing effect of metformin are carried out via 
activation of AMPK (Hawley et al., 2002), simulating the very first effects on physical 
activity in skeletal muscle. Finally, Exercise is an ideal lifestyle intervention suitable and 
rightful to all obese patients, due to its counteracting measures against the molecular 
derangements observed in obesity, modulating local and systemic metabolic disturbances. 
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